Abstract: The present disclosure provides antibodies capable of distinguishing between wild-type FGFR3 and FGFR3 S249C mutants. Using these antibodies, antigen-binding molecules capable of selectively damaging tumor cells expressing an FGFR3 S249C mutant were constructed.

Abstract: A storage battery management method, performed by a communication terminal includes: acquiring, from the first storage battery, storage battery information of the first storage battery; storing, in a memory, the acquired storage battery information when the storage battery information is acquired from the first storage battery; receiving a first request from a management server, the first request requesting the communication terminal to transmit first storage battery information to the management server, the first storage battery information being the storage battery information of the first storage battery; and transmitting, when the communication terminal receives the first request from the management server, the first storage battery information to the management server, based on the storage battery information stored in the memory.

Abstract: The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.

Abstract: The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.

Abstract: A storage battery management method, performed by a communication terminal includes: acquiring, from the first storage battery, storage battery information of the first storage battery; storing, in a memory, the acquired storage battery information when the storage battery information is acquired from the first storage battery; receiving a first request from a management server, the first request requesting the communication terminal to transmit first storage battery information to the management server, the first storage battery information being the storage battery information of the first storage battery; and transmitting, when the communication terminal receives the first request from the management server, the first storage battery information to the management server, based on the storage battery information stored in the memory.

Abstract: The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.

Abstract: An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.

Abstract: A storage battery management method which is performed in a communication terminal, the storage battery management method including: performing communication with a storage battery which is an object to be managed and acquiring storage battery information on the use of the storage battery; storing the acquired storage battery information every time the storage battery information is acquired; and performing communication with a management server managing the storage battery and providing, only when accepting a request for provision of the storage battery information from the management server, storage battery information of the stored storage battery information, the storage battery information in accordance with the request for provision, to the management server.

Abstract: The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.

Abstract: An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.

Abstract: If a customer has picked up a product from a display shelf, a display device displays first sales promotion information. In an information providing system, if the customer has not been attracted to the product and has returned the product to the display shelf, the display device displays second sales promotion information, which is different from the first sales promotion information. By displaying the different pieces of sales promotion information using the display device provided near the product, it is possible to promote the product to the customer in two different ways, thereby stimulating the customer's desire to buy the product and reducing loss in opportunities to sell the product.

Abstract: The present invention relates to quinazolinone and isoquinolinone derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present inventors successfully identified novel gatekeeper mutations for FGFR. Further, they discovered that mutant FGFR having the mutations demonstrate resistance to known FGFR inhibitors such as AZD4547, and at the same time demonstrate sensitivity to specific compounds. Mutant polypeptides having the mutations may be used as biomarkers in cancer treatment by FGFR inhibitors to prevent the development of side effects in therapy by conventional FGFR inhibitors, and to control the therapeutic mode for receiving the best therapeutic effect, thus making individualized treatment possible.

Abstract: The present invention relates to quinazolinone and isoquinolinone derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.

Abstract: An electricity storage control device that transmits a charging rate of at least one of electricity storage devices to a management device that manages electric power interchange between the electricity storage devices, the electricity storage control device including: a charge information acquisition unit that acquires the charging rate of the at least one electricity storage device as a first charging rate; a communication unit that transmits the first charging rate to the management device; and a control unit that causes the communication unit to transmit, instead of the first charging rate, a second charging rate that charge and discharge determining information defines as the charging rate at which the charge and discharge are prohibited, when the charge and discharge determining information defines the first charging rate as the charging rate at which the charge and discharge are permitted.

Abstract: a storage battery management method which is performed in a communication terminal, the storage battery management method including: performing communication with a storage battery which is an object to be managed and acquiring storage battery information on the use of the storage battery; storing the acquired storage battery information every time the storage battery information is acquired; and performing communication with a management server managing the storage battery and providing, only when accepting a request for provision of the storage battery information from the management server, storage battery information of the stored storage battery information, the storage battery information in accordance with the request for provision, to the management server.

Abstract: The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.

Abstract: A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a C6-10 aryl group; R1 and R2 independently represent H, OH, X, CN, NO2, a C1-4 haloalkyl group, a C1-6 alkyl group, or the like <R1 and R2 together form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group>; R3 represents H, a C1-5 alkyl group, a C6-10 aryl group, a C1-5 alkyl group, or a C1-4 haloalkyl group; and R4 represents H, X, a C1-3 alkyl group, a C1-4 haloalkyl group, OH, CN, NO2, or the like.

Abstract: The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.